|
|
2008, Nov: Breaking news by Thomson Reuters: A recent publication of Pharmahungary (Ferdinandy P, Schulz R, Baxter GF. Interaction of cardiovascular risk factors with myocardial ischemia/reperfusion injury, preconditioning and postconditioning. Pharmacol Rev 59:418-458, 2007) has been selected by Essential Science Indicators as a Fast Breaking Paper in the field of Pharmacology & Toxicology 2008 Nov: Pharmahungary opens up new office at Graphisoft Park, Budapest. 2008, January: PharmaHungary get fund in a consortium to develop "Platform of mouse and human embryonic stem cell-derived cardiomyocyte test systems for drug development" 2007, Nov: Press release: Issue 11-12/2007 European Biotechnology News Hungarian National Office for Research
and Technology signed agreement with MMPharma™ (www.mmpharma.com)
consortium in October 2007 on 1.2 million Euros financial support of
the consortium’s 3 year drug discovery program for Matrix
Metalloproteinase Inhibitors (MMPIs) for the treatment of
cardiovascular diseases. The consortium, consisting 3 biotech companies
and 3 academic research groups, was initiated in 2005 by Pharmahungary™
(Szeged, Hungary) a young innovative company active in preclinical and
clinical pharmacological services, when Dr. Péter Ferdinandy, CEO and
founder of Pharmahungary™, and his academic research group published
that MMPIs might mimic endogenous cardioprotection, therefore, MMPIs
can be used to reduce infarct size in normal and hyperlipidemic animal
models. InFarmatik (Budapest, Hungary), a supplier of chemical products
and services since 1999 for drug discovery programs for biotech/pharma
companies was invited to participate in the MMPharma consortium, to act
as a chemistry engine for the MMPharma project. OntoChem a German
chemoinformatic company was contracted to use its proprietary tools to
facilitate design phase of MMPharma drug discovery.
I am convinced, Dr. Péter Ferdinandy CEO of Pharmahungary says, that we can finish this MMPI program successfully. The consortium has all specialized expertise for from in silico chemistry to preclinical pharmacology. E.g. InFarmatik has the diversity of building blocks and scaffolds sufficient for generating novel leads with firm IP rights. This collaboration can establish an efficient R&D consortium which can extend research for other therapeutic fields which Pharmahungary wishes to explore in the future. I believe, Dr. László Kovacs, CEO of InFarmatik states, that MMPharma project is a good opportunity to show InFarmatik’s efficiency in performing complex services in drug discovery projects. Dr. Lutz Weber CEO of OntoChem (Halle, Germany) confirms that the results from cardiovascular MMPI projects can be successfully applied on other important areas like neurodegenerative and anticancer fields. The consortium’s newly launched website (www.MMPharma.com) introduces the objectives of the consortium and shows early non-confidential results. |